same excipients except no hypromellose
Sponsors
Sanofi-Aventis Recherche & Developpement, Sanofi-Aventis Research & Development
Conditions
Lung transplant rejectionchronic graft versus host disease
Phase 3
A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by open-label
extensions, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft
dysfunction (CLAD) following bilateral lung transplantation
RecruitingCTIS2023-503462-23-00
Start: 2023-12-28Target: 77Updated: 2025-12-18
A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)
Active, not recruitingCTIS2023-505394-32-00
Start: 2025-02-06Target: 157Updated: 2025-09-24